2.41
-0.035(-1.43%)
Currency In USD
| Previous Close | 2.44 |
| Open | 2.47 |
| Day High | 2.57 |
| Day Low | 2.39 |
| 52-Week High | 7.85 |
| 52-Week Low | 1.29 |
| Volume | 1.07M |
| Average Volume | 1.49M |
| Market Cap | 263.86M |
| PE | -1.86 |
| EPS | -1.29 |
| Moving Average 50 Days | 2.5 |
| Moving Average 200 Days | 3.33 |
| Change | -0.04 |
If you invested $1000 in Annexon, Inc. (ANNX) since IPO date, it would be worth $135.42 as of August 18, 2025 at a share price of $2.405. Whereas If you bought $1000 worth of Annexon, Inc. (ANNX) shares 3 years ago, it would be worth $425.66 as of August 18, 2025 at a share price of $2.405.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
GlobeNewswire Inc.
Aug 07, 2025 8:30 PM GMT
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
GlobeNewswire Inc.
Jul 24, 2025 11:00 AM GMT
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innova
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
GlobeNewswire Inc.
Jun 18, 2025 8:05 PM GMT
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to S